Consensus Spero Therapeutics, Inc. Börse Stuttgart

Stocks

2HA

US84833T1034

Biotechnology & Medical Research

Market Closed - Börse Stuttgart 15:55:33 2026-09-09 EDT			5-day change	1st Jan Change
1.001 ^EUR	-1.86%		-0.78%	-46.48%

08-12	Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

2b8a84838026217a66d7e7.tdDrY8KnpfpZcut_h_seI89X4gNT-BHnd9aFFdqZyks.3bufK5OK1p9rC94Y7sN1W6oBslwMtmaRAPvMeZPBnRTTj5EE8PWXihUYog~770fa2b578b9203a3bd4f8a87a24da13

Analysts' recommendations: Spero Therapeutics, Inc.

25-10-21	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
24-12-20	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
24-11-18	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
24-08-06	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
23-08-14	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT
22-09-26	HC Wainwright Adjusts Spero Therapeutics' Price Target to $6 From $7, Maintains Buy Rating	MT
22-09-22	Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line	MT
22-08-15	HC Wainwright Adjusts Spero Therapeutics' Price Target to $7 From $10, Keeps Buy Rating	MT
22-07-01	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	MT
22-05-23	HC Wainwright Adjusts Spero Therapeutics' Price Target to $10 from $37, Keeps Buy Rating	MT
22-05-20	Berenberg Bank Downgrades Spero Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $44	MT
22-05-17	Cantor Fitzgerald Lowers Spero Therapeutics' Price Target to $5 From $27, Overweight Rating Kept	MT
22-05-04	Cowen Downgrades Spero Therapeutics to Market Perform From Outperform	MT
22-05-04	Evercore ISI Downgrades Spero Therapeutics to In-Line From Outperform, Adjusts Price Target to $2 From $40	MT
22-04-18	HC Wainwright Adjusts Spero Therapeutics' Price Target to $37 From $43, Maintains Buy Rating	MT
22-03-21	HC Wainwright Adjusts Spero Therapeutics' Price Target to $43 From $40, Keeps Buy Rating	MT
21-11-16	Berenberg Bank Adjusts Spero Therapeutics PT to $44 From $47, Maintains Buy Rating	MT
21-10-01	Spero Therapeutics : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform	MT
21-03-12	Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $20 From $21, Maintains Outperform Rating	MT
21-01-22	Spero Therapeutics : HC Wainwright Adjusts Spero Therapeutics' Price Target to $40 From $33, Keeps at Buy	MT
21-01-05	Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $21 From $19, Maintains Outperform Rating	MT
20-12-16	Spero Therapeutics : Berenberg Starts Spero Therapeutics at Buy With $47 Price Target	MT
20-11-23	Spero Therapeutics : HC Wainwright Adjusts Price Target on Spero Therapeutics to $33 From $28, Reiterates Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+19.65%
	ARGENX SE					+16.26%
	INSMED INCORPORATED					+60.29%
	BIONTECH SE					+20.86%
	WUXI BIOLOGICS (CAYMAN) INC.					+17.06%
	GENMAB A/S					+13.34%
	PHARMAESSENTIA CORPORATION					-0.55%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+26.73%
	EXELIXIS, INC.					-6.91%
	Average					+18.52%
	Weighted average by Cap.					+19.95%